BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25853582)

  • 1. Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer.
    Li J; Veltri RW; Yuan Z; Christudass CS; Mandecki W
    PLoS One; 2015; 10(4):e0122249. PubMed ID: 25853582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis.
    Brown DA; Stephan C; Ward RL; Law M; Hunter M; Bauskin AR; Amin J; Jung K; Diamandis EP; Hampton GM; Russell PJ; Giles GG; Breit SN
    Clin Cancer Res; 2006 Jan; 12(1):89-96. PubMed ID: 16397029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
    Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
    [No Abstract]   [Full Text] [Related]  

  • 4. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
    Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
    Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
    Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml.
    Lucarelli G; Fanelli M; Larocca AM; Germinario CA; Rutigliano M; Vavallo A; Selvaggi FP; Bettocchi C; Battaglia M; Ditonno P
    Prostate; 2012 Nov; 72(15):1611-21. PubMed ID: 22430630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of serum zinc improves prostate cancer detection efficiency in patients with PSA levels between 4 ng/mL and 10 ng/mL.
    Li XM; Zhang L; Li J; Li Y; Wang HL; Ji GY; Kuwahara M; Zhao XJ
    Asian J Androl; 2005 Sep; 7(3):323-8. PubMed ID: 16110361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range.
    Kefi A; Irer B; Ozdemir I; Tuna B; Goktay Y; Yorukoğlu K; Esen A
    Urol Int; 2005; 75(3):222-6. PubMed ID: 16215309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    Int J Urol; 2005 Oct; 12(10):881-5. PubMed ID: 16323981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA density improves prediction of prostate cancer.
    Verma A; St Onge J; Dhillon K; Chorneyko A
    Can J Urol; 2014 Jun; 21(3):7312-21. PubMed ID: 24978363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
    Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
    Steuber T; Vickers A; Haese A; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2007 Apr; 120(7):1499-504. PubMed ID: 17205511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.